Exosens/€EXENS

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Exosens

Exosens is a high-tech company specializing in the innovation, development, manufacturing, and sale of advanced electro-optical technologies in amplification, detection, and imaging. Its product portfolio includes traveling wave tubes, advanced cameras, neutron and gamma detectors, instrument detectors, and light intensifier tubes, serving sectors such as defense, life sciences, industrial control, and nuclear energy. Founded over 85 years ago, the company rebranded from Photonis Group to Exosens in September 2023 to reflect its expanded technological scope. Headquartered in Mérignac, France, Exosens operates 12 production and R&D sites across Europe and North America, employing over 1,700 individuals. The company's strategic positioning is bolstered by sustained investments in innovation and a series of acquisitions, including Xenics, Proxivision, Telops, and Elmul since December 2022, enhancing its capabilities in detection and imaging technologies. (,)

Ticker

€EXENS
Sector
Industrials

Primary listing

PAR

Employees

1,400
Headquarters
Mérignac, France
Website
www.exosens.com

Exosens Metrics

BasicAdvanced
€2.2B
43.41
€0.99
-
€0.10
0.23%

Bulls say / Bears say

Exosens delivered first-quarter 2025 revenue of €104.9 million, topping the consensus forecast of €101 million, confirming strong demand and leaving the company on course to meet full-year targets (Reuters)
In March 2025, Exosens committed €20 million to build its first U.S. factory in Sturbridge, Massachusetts, boosting its production capacity to serve American defense customers and aiming to capture up to 45% of the global night vision market from 2027 (Reuters)
The German parliament’s approval of the third OCCAR night vision contract option—ordering 25,000 binoculars—initiates further Photonis tube orders under the long-term agreement for 2025–2027, strengthening medium-term revenue visibility (Bloomberg/Reuters)
Kepler Cheuvreux downgraded Exosens to “Reduce” from “Hold”, warning that the growth potential of the defense sector is limited by the company’s current production capacity and that the share price is “higher than investors should pay” (Reuters)
The broker also projects Exosens’ effective tax rate will increase to about 25% over the next two to three years as tax-loss carry-forwards run out, which could significantly reduce net earnings and free cash flow (Reuters)
Exosens’ Detection & Imaging division posted a 13% year-on-year like-for-like revenue decline in Q1 2025, as Telops struggled with U.S. tariff risks and reduced federal science budgets, highlighting volatility in this segment (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €EXENS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs